The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.
Drug Advisory Committee May 2026 Meeting Outcome
Generic / Brand name
Meeting outcome
Primary reason for unsuccessful application1
1
Bimekizumab (Bimzelx)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient / Alternative(s) available in HADF with comparable benefits
2
Budesonide MR (Nefecon)
Approved
3
Dabrafenib / Trametinib (Tafinlar / Mekinist)
Approved
4
Denosumab (Xgeva)
Approved
5
Deucravacitinib (Sotyktu)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient / Alternative(s) available in HADF with comparable benefits
6
Eptinezumab (Vyepti)
Unsuccessful
Alternative(s) available in HADF with comparable benefits
7
Eravacycline (Xerava)
Approved
8
Etranacogene dezaparvovec (Hemgenix)
Unsuccessful
Alternative(s) available in HADF with comparable benefits
The justification of the treatment’s cost in relation to its benefits is insufficient
14
Tirzepatide (Mounjaro)
Pending
Pending further information
15
Tislelizumab (Tevimbra)
Approved
16
Varenicline (APO-Varenicline)
Approved
17
Zolbetuximab (Vyloy)
Approved
1 The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.
DAC Meeting Outcome
